DOCSLIB.ORG

Copyrighted Material

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

JWBK208-IND-II August 12, 2008 16:22 Char Count= 0 Index of General Terms 395 Index of General Terms 3D clusters (in cytology) polymorphous low grade 131 adiposis dolorosa 281 mesothelial 360 prostatic 220, 222, 224 adnexal tumours 292–4 urine 365 adenoid adrenal medullary chromaffin adenocarcinoma 361 basal carcinoma 234 paraganglioma 276 ␣1-antitrypsin 157 basal epithelioma 234 adrenal pathology 53–4, 275–7, 383 acantholytic squamous cell carcinoma cystic carcinoma 131, 369 adrenocortical adenoma 275–6 285 pharyngeal tonsil 38 adrenocortical carcinoma (ACC) acanthoma 282, 283, 292 adenoma 130–1, 200 275–6 accessory auricles 199 adrenocortical 275–6 adrenocorticotrophic hormone acetic acid artefact 357 basal cell 130–1, 223 (ACTH) 275, 278 achalasia of the cardia 135 bile duct 172 adult achondroplasia 330 bronchioalveolar 91 granulosa cell tumour 249 acinar cell carcinoma/dysplasia 177 Brunner’s gland 142 large bile duct obstruction 164 acinar zones (of liver) 156 canalicular 131 renal tumours 49 acinic cell carcinoma 132, 369 duct 264 respiratory distress syndrome 383 acquired immunodeficiency dysplasia 149–50 T-cell leukaemia 115–16 syndrome (AIDS, see also HIV) flat 149–50 advanced practitioners 359 165, 306–7, 346–7, 364 follicular 268–9 adventitious bursa 342 acral naevus 288 gastric 138 AFP 19 acrodermatitis enteropathica 304 hepatocellular 169–70 age-related changes 68, 75, 196–7, ACTH 275, 278 hyalinising trabecular 271 201 actinic malignum 235 age-related macular degeneration keratosis 283 metanephric 216 (AMD) 196–7 lentigo 288–9 microcystic 177 Agenda for Change 24–5 reticuloid 299 nephrogenic 218 aggressive Actinomyces spp. 343–344, 22, 239, of the nipple 259–60 angiomyxoma 317 357, 371 parathyroid 274 osteoblastoma 335 acute Pick’s 227 AIDS cholangiopathy 165 cholecystitis 173–4 pleomorphic salivary 130, 368 AIDS-associated malignancies diffuse proliferative polypoidal 149–50 347 glomerulonephritis 202 renal 216 AIDS-defining illnesses (ADI) 346, disseminated encephalomyelitis 183 serous microcystic 177 364 endometriosis 239 serrated 149–50 AIN 152 febrile neutrophilic dermatosis 300 sporadic 149–50 air embolism 390 haemorrhagic leucoencephalitis 183 adenomatous Albers-Sch¨onberg marble bone haemorrhagic hyperplasia (lung) 91 disease 330 leucoencephalomyelitis 183 hyperplasia (prostate) 220–1 Alcian blue 12 haemorrhagic leucoencephalopathy nodules (liver) 171 alcoholic 183 polyps 138, 149–50, 220 fixatives 7 hepatitis 158–9 adenomyoma gastropathy 137 lymphoblastic leukaemia 16, 97, atypical polypoid 239, 242 hepatitis 157 101, 103–5, 228, 253 biliary tree 173 steatohepatitis 157 myeloid leukaemia 103, gallbladder 174 alimentary tract 126–55 4, 16, 99–104, 107–8, 123, 300 uterus 239 alkaline phosphatase (ALP) 11, 15, pancreatitis 175 adenosarcoma 242–3 53, 332, 336, 337 pouchitis 147 COPYRIGHTEDtamoxifen and 238, 254 MATERIALALL 16, 97, 101, 103–5, 228, 253 pyelonephritis 206 vs. endometrial stromal tumours 242 allograft rejection see transplants radiation effects 305 vs. granulosa cell tumour 249 alopecia 295 rheumatic fever 76–7 adenosis ALP 11, 15, 53, 332, 336, 337 tubular necrosis 206 atypical apocrine 262, 373 Alport’s disease 205 villitis 63 microglandular 262 alveolar adamantinoma 335 prostate 220–1 capillary dysplasia 56 adenocarcinoma 91–2, 219, 361 sclerosing (breast) 262 pathology 58 basal cell 130–1 sclerosing (prostate) 221 radial counts 393 bronchial 369–70 sclerosing (salivary) 134 soft part sarcoma 323 ductal 176 vaginal 232 Alzheimer’s disease 181 endometrioid 92 adenosquamous carcinoma (ASC) 92 AMD 196–7 invasive 234–5 ADH 258–9 ameloblastic fibroma 128–9 minimal deviation 235 adipose 313–15 ameloblastoma 128 Diagnostic Criteria Handbook in Histopathology: A Surgical Pathology Vade Mecum by Paul J. Tadrous Copyright C 2007 by John Wiley & Sons, Ltd. JWBK208-IND-II August 12, 2008 16:22 Char Count= 0 Index of General Terms 396 AML 103, 4, 16, 99–104, 107–8, 123, antiphospholipid antibody syndrome ASH 157 300 61–2, 351 Askin tumour of chest wall 58 amnion nodosum 63 aortic dissection 73 Aspergillus spp. 22, 345, 370 ampulla of Vater 46 aphthae 126–7, 144–5 asthma 86 amputation neuroma 317 apical granuloma 128 astrocytoma 185 amyloid 11 apocrine carcinoma 293 asymptomatic proteinuria 201 angiopathy 72 aponeuroses 323–4 atherosclerotic aneurysms 72 colonic 146 appendix 46, 152 atrophy 358 eye 194 applied anatomy 36–43 atypical skin 300 appraisals 32 acinar cell nodules 177 tumour 94, 194 arachnoid nodules 94 adenomatous hyperplasia 91, 220–1 anal canal 152 ARDS 383 adenomatous nodules 171 anal intra-epithelial neoplasia (AIN) Arias-Stella reaction 232, 236, 237, decubital fibroplasia 311 152 253 ductal hyperplasia 258–9 analgesic nephropathy 206 arrhythmogenic right ventricular fibroxanthoma 325 anaphylaxis 382 dysplasia (ARVD) 78, 385 haemangioma of the breast 320 anaplastic artefact(s) hyperplasia 51, 238 astrocytoma 185 acetic acid 357 lipoma 313 carcinoma 272, 368 air bubbles (vs. air embolism) 390 lobular hyperplasia 262 large cell lymphoma 105, 109, 116 alcohol fixation 7 nodular proliferations in a meningioma 186 birefringent particles (in synovial congenital naevus 288 myeloma 109 fluid) 375 polypoid adenomyoma 239 oligo/oligoastrocytoma 186 capsule/halo (in Histoplasma) 345 small acinar proliferations 222 seminoma 225 cirrhosis and 161 vascular lesions post radiotherapy Wilms’ tumour 60 cracks (in FCL) 112 320 anatomy 36–43 crush (in carcinoid/SmCC/spinal aural polyp 199, 319 ancillary techniques 362–3 cord) 93, 389 autoimmune ancillary tests 387 dyscohesion (in breast FNA) 371, diseases 86–7 androgen blockade therapy 224 373 hepatitis 161 aneurysmal bone cysts (ABC) 331, dysplasia vs. 136 pancreatitis 175 333 erosion vs. 127 plexopathy 154 aneurysms 72–3 FNA / needle track 265, 269 sialadenitis 132–3 angina 75 formalin fixation (unbufferred) 7, autopsy 3, 23, 377–94 angioblastoma of Nakagawa 319 383 limited 386–7 angiocentric frozen section 4 performance lymphoid proliferations 91 ice crystal (in muscle) 43, 189 recommendations/guidance 378 T-cell lymphoma 115 iodine (and CIN) 233 perinatal 392–3 angiodysplasia 148 liver 156 see also postmortem angiofollicular lymph node mercurial fixation 16 autosomal dominant polycystic hyperplasia 119–20 nuclear clearing (due to kidney disease (ADPCKD) angiography 386 biotin/fixation) 267, 270, 272 212–13 angioimmunoblastic RBCs in alveoli 87 autosomal recessive polycystic kidney lymph node reaction 115 retraction (in lacunar cells) 4, 117 disease 213 lymphadenopathy with sampling (in muscle Bx) 189 avascular dysproteinaemia 115 sclerosing HCC (footnote) 171 necrosis 330 T-cell lymphoma 115 sickling of RBCs 383 villi 62 angiokeratoma circumscriptum 285 smearing (vs. vascular invasion) 205 angioleiomyolipoma 314 spindling (in Ewing’s) 336 B-cell angiolipoma 313 tangiential sectioning 205 lymphoma 110–14, 302 angiolymphoid hyperplasia with thick section (syncytial knots) 61 persistent polyclonal lymphocytosis eosinophilia 318 arterial 101 angiomatosis 319–23 dissection 73 reactions 109 angiomyofibroblastoma 317 embolism 390 bacillary angiomatosis 319 angiomyolipoma 216, 314 pathology 68, 69 bacilli 343 angiomyxoma 317–18 pulmonary hypertension 88 bacterial angiosarcoma 320–1 arteriohepatic dysplasia 164 colitis 143 ankylosing spondylitis 194 arterioles/arteriolosclerosis 68, 69 infection 343–4 anti-rejection drug toxicity 209–10 arteriosclerosis 68 balanitis xerotica obliterans (BXO) antibodies arteritis 44, 69, 70 215 anticardiolipin 351 arthritis 340–1 balloon cells 197 antiphospholipid antibody articular pathology 339–42 Banff grading 209, 208, 165 syndrome 61–2, 351 ARVD 78, 385 Barium 148, 341, 32 layering methods 9 ASAP/ASAPUS 222 Barrett’s, 135, 45 site selective 363 asbestos bodies 86, 48, 371 epithelium 135 anticardiolipin antibody 351 asbestosis 85–6 dysplasia 136 antigens 19, 107–9 ascending cholangitis 166–7 oesophagus 135 JWBK208-IND-II August 12, 2008 16:22 Char Count= 0 Index of General Terms 397 Bartholin gland cysts 232 ␣1-antitrypsin 157, 170 pathology 329–39 Bartonella spp. 167 aortic 11 sarcoma 53 basal cell asbestos 86, 48, 371 tumours 332–9 adenocarcinoma 130–1 Aschoff 76–7 BOOP 85 adenoma 130–1, 223 asteroid 194 borderline adenomatosis 223 Barr 353 cutaneous T-cell proliferations 302 carcinoma 48, 223, 284, 292 blue 84, 370 mucinous tumours 245 hyperplasia 223 Call-Exner 249, 252 nuclear changes 354, 358 immunohistochemistry 18 Call-Exner-like 227 seminoma 225 papilloma 282–3 carotid 11 serous tumours of the peritoneum basal ganglia degenerations 182 Civatte 297, 306 255 basal-like carcinoma (breast) 265 colloid 300 teratoma 225 basement membranes 11 Councilman 159, 163, 166 Borst-Jadassohn phenomenon 282 Baylisascaris spp. 349 Creola 369 Bouin’s fixative 7 BCC 48, 223, 284, 292 cytoid 185, 195 Bowel Cancer Screening Program 32 BCDA 136 Donovan 109, 343 Bowenoid actinic keratosis 283 Becker’s muscular dystrophy 191 Dutcher 104, 361, 362 Bowenoid papulosis 229 Becker’s pigmented hairy epidermal elementary 185 Bowen’s disease 229, 283 naevus 287 embryoid 252 BPOP 333 Beh¸cet’s ferruginous 86 brain 36, 187–8, 383, 388 arthritis 341 fibrous 278 breast colitis 144, 145 foreign 101 angiomatosis 319 disease 194 fruiting 345 atypical haemangioma 320 benign Gamna-Gandy 79, 122 atypical vascular lesions 320 breast lesions 265–6 giant lamellar 91 basal-like carcinoma 265 familial chronic pemphigus 304 haematoxyphile 204 benign lesions 265–6 familial haematuria 205 Herring 277 carcinoma 17, 52, 260–262, 265 fibrous histiocytoma 326 Hirano 181 cytopathology
Recommended publications
  • CD133 Expression in Placenta Chorioangioma Presenting As a Giant Asymptomatic Mass

    CD133 Expression in Placenta Chorioangioma Presenting As a Giant Asymptomatic Mass

    medicina Case Report CD133 Expression in Placenta Chorioangioma Presenting as a Giant Asymptomatic Mass Gianluca Di Massa 1,†, Guglielmo Stabile 2,† , Federico Romano 2 , Andrea Balduit 3 , Alessandro Mangogna 2,* , Beatrice Belmonte 4 , Pina Canu 1, Emma Bertucci 5, Giuseppe Ricci 2,6,‡ and Tiziana Salviato 1,‡ 1 Department of Diagnostic, Clinic and Public Health Medicine, University of Modena and Reggio Emilia, 41125 Modena, Italy; [email protected] (G.D.M.); [email protected] (P.C.); [email protected] (T.S.) 2 Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Via dell’Istria, 65/1, 34137 Trieste, Italy; [email protected] (G.S.); [email protected] (F.R.); [email protected] (G.R.) 3 Department of Life Sciences, University of Trieste, 34127 Trieste, Italy; [email protected] 4 Tumor Immunology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, 90134 Palermo, Italy; [email protected] 5 Prenatal Medicine Unit, Obstetrics and Gynecology Unit, Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, 41125 Modena, Italy; [email protected] 6 Department of Medical, Surgical and Health Science, University of Trieste, 34129 Trieste, Italy * Correspondence: [email protected]; Tel.: +39-320-612-3370 † These authors contributed equally to this article. Citation: Di Massa, G.; Stabile, G.; ‡ These authors contributed equally to this article. Romano, F.; Balduit, A.; Mangogna, A.; Belmonte, B.; Canu, P.; Abstract: Background: Placental chorioangioma is the most common benign non-trophoblastic neo- Bertucci, E.; Ricci, G.; Salviato, T.
  • Placenta 111 (2021) 33–46

    Placenta 111 (2021) 33–46

    Placenta 111 (2021) 33–46 Contents lists available at ScienceDirect Placenta journal homepage: www.elsevier.com/locate/placenta Review Placental pathology in cancer during pregnancy and after cancer treatment exposure Vera E.R.A. Wolters a, Christine A.R. Lok a, Sanne J. Gordijn b, Erica A. Wilthagen c, Neil J. Sebire d, T. Yee Khong e, J. Patrick van der Voorn f, Fred´ ´eric Amant a,g,* a Department of Gynecologic Oncology and Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute - Antoni van Leeuwenhoek and University Medical Centers Amsterdam, Plesmanlaan 121, 1066, CX Amsterdam, the Netherlands b Department of Gynaecology and Obstetrics, University of Groningen, University Medical Center Groningen, CB 20 Hanzeplein 1, 9713, GZ Groningen, the Netherlands c Scientific Information Service, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX Amsterdam, the Netherlands d Department of Paediatric Pathology, NIHR Great Ormond Street Hospital BRC, London, WC1N 3JH, United Kingdom e SA Pathology, Women’s and Children’s Hospital, 72 King William Road, North Adelaide, SA5006, Australia f Department of Pathology, University Medical Centers Amsterdam, Location VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands g Department of Oncology, KU Leuven, Herestraat 49, 3000, Leuven, Belgium ARTICLE INFO ABSTRACT Keywords: Cancer during pregnancy has been associated with (pathologically) small for gestational age offspring, especially Placenta after exposure to chemotherapy in utero. These infants are most likely growth restricted, but sonographic results Cancer are often lacking. In view of the paucity of data on underlying pathophysiological mechanisms, the objective was Pregnancy to summarize all studies investigating placental pathology related to cancer(treatment).
  • Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, P53, FGFR3 and TATI in Bladder Cancers

    Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, P53, FGFR3 and TATI in Bladder Cancers

    International Journal of Molecular Sciences Review Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers Milena Matuszczak and Maciej Salagierski * Department of Urology, Collegium Medicum, University of Zielona Góra, 65-046 Zielona Góra, Poland; [email protected] * Correspondence: [email protected] Received: 16 April 2020; Accepted: 5 May 2020; Published: 9 May 2020 Abstract: The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice. Keywords: biomarkers; bladder cancer; tumor markers; prognosis 1. Introduction: Bladder Cancer Issues and Biomarkers Bladder cancer is the most common urinary site of malignancy and the second most common reason of cancer deaths from the genitourinary tract after prostate cancer in the United States, with 81,400 new cases and 17,980 deaths in the year 2020 [1]. Globally there are about 430,000 new cases diagnosed each year [2].
  • NMP22) As a Tumour Marker in Bladder Cancer Patients

    NMP22) As a Tumour Marker in Bladder Cancer Patients

    NOWOTWORY Journal of Oncology • 2005 • volume 55 Number 4 • 300–302 Evaluation of the urinary nuclear matrix protein (NMP22) as a tumour marker in bladder cancer patients Maria Kowalska1, Janina Kamiƒska1, Beata Kotowicz1, Ma∏gorzata Fuksiewicz1, Alicja Rysiƒska1, Tomasz Demkow 2, Tomasz Kalinowski 2 Introduction. The aim of this study was to evaluate the clinical use of the urinary nuclear matrix protein 22 (NMP22) assessment in bladder cancer patients. Patients and methods. 98 patients with bladder cancer were examined. All tumours were verified histopathologically. Urine samples were collected before cystoscopy and assayed for NMP22 levels with Diagnostic Products Corporation tests. Urine samples of 15 healthy volunteers served as controls. For the statistical analysis the Mann-Whitney test was employed. Results. Urine NMP22 concentrations were significantly higher (p<0.0003) in patients with bladder cancer than in controls. No significant differences between the NMP22 concentrations in patients with complete remission and patients with recurrent disease were found. Conclusions. Urinary NMP22 is a potential marker for the diagnosis of bladder cancer, but not for the differentiation between disease-free patients and those with recurrent disease. Ocena przydatnoÊci oznaczania NMP22 w moczu jako markera nowotworowego u chorych na raka p´cherza Ws t ´ p. Celem pracy by∏o zbadanie, czy oznaczanie markera nowotworowego NMP22 mo˝e byç pomocne w monitorowa- niu chorych na raka p´cherza. Pacjenci i metody. Do badania zakwalifikowano 98 chorych z potwierdzonym histologicznie rakiem p´cherza. Próbki moczu pobierano przed cystoskopià. St´˝enie NMP22 w moczu oznaczano zestawami firmy DPC. W∏asne normy ustalono w oparciu o oznaczenia st´˝eƒ NMP22 w grupie 15 zdrowych osób.
  • Liquid Biopsy Biomarkers in Urine: a Route Towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer

    Liquid Biopsy Biomarkers in Urine: a Route Towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer

    Journal of Personalized Medicine Review Liquid Biopsy Biomarkers in Urine: A Route towards Molecular Diagnosis and Personalized Medicine of Bladder Cancer Matteo Ferro 1,† , Evelina La Civita 2,†, Antonietta Liotti 2, Michele Cennamo 2, Fabiana Tortora 3 , Carlo Buonerba 4,5, Felice Crocetto 6 , Giuseppe Lucarelli 7 , Gian Maria Busetto 8 , Francesco Del Giudice 9 , Ottavio de Cobelli 1,10, Giuseppe Carrieri 9, Angelo Porreca 11, Amelia Cimmino 12,* and Daniela Terracciano 2,* 1 Department of Urology of European Institute of Oncology (IEO), IRCCS, Via Ripamonti 435, 20141 Milan, Italy; [email protected] (M.F.); [email protected] (O.d.C.) 2 Department of Translational Medical Sciences, University of Naples “Federico II”, 80131 Naples, Italy; [email protected] (E.L.C.); [email protected] (A.L.); [email protected] (M.C.) 3 Institute of Protein Biochemistry, National Research Council, 80131 Naples, Italy; [email protected] 4 CRTR Rare Tumors Reference Center, AOU Federico II, 80131 Naples, Italy; [email protected] 5 Environment & Health Operational Unit, Zoo-Prophylactic Institute of Southern Italy, 80055 Portici, Italy 6 Department of Neurosciences, Sciences of Reproduction and Odontostomatology, University of Naples Federico II, 80131 Naples, Italy; [email protected] 7 Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, 70124 Bari, Italy; [email protected] 8 Department of Urology and Organ Transplantation,
  • California Tumor Tissue Registry

    California Tumor Tissue Registry

    " CALIFORNIA TUMOR TISSUE REGISTRY California Tumor Tissue Registry c/o: Departme.nt of Pathology and Human Anatomy Lorna Linda University Sebool of Medicine 11021 Campus Avenue, AH 335 Lorna Linda, California 92350 (909) 824-4788 FAX: (909) 478-4188 CON"ntiDUTOR: WllllanoTalbert, M.D. CASE NO. 1 ·NOVEMBER 1995 Long Beach, CA TISSUE FROM: Sple<on ACCESSION #27748 CLINICAL ABSTRACT: This 77-year-old maJe. bad a 1-1!2 year history of a myelodysplastic syndrome, Ilea ted with blood transfusions for anemia. G.I. bleeding with tany stools and a hemoglobin of 5.21<d to admission about two weeks prior to his death. He became febrile. Blood and urine cullures were sterile. Renal failure developed. He became obtunded and died. He did not have a leukenlic peripheral blood picture. GROSS PATHO LOGV: Autopsy revealed a 1750 gram spleen with a splenic ''abscess•• which was partially ruptured and contained by surrounding tissue. CONTRIDUTOR: William Talbert, M.D. CASE NO. 2 • NOVE~ffiER 1995 Long Beach, CA TISSUE FROM: Lung ACCESSION 1127760 CLINl CAL ABSTRACT: This 23-year-old Asian female bad hemoptysis for two years. Chest film revealed a 1.0 em mass which grew to 4 em under observation. Iron deficiency anemia was diagnosed preoperatively, with a hemoglobin of 10.7 grams. Needle biopsy of the mass revealed tissue with the same diagnosis as that made on the resected specimen. A right upper lobe lobectomy was performed . GROSS PATROLOGV: The 120 gram lung was 12 x 7 x 3.5 em. A 3.5 em well-cireuonscribed nodule was near the bronchial margin.
  • Appendix E: Authorization Guidelines for Laboratory, Ob/Gyn, and Radiology Services (Auto Pay List)

    Appendix E: Authorization Guidelines for Laboratory, Ob/Gyn, and Radiology Services (Auto Pay List)

    KAISER PERMANENTE OF OHIO APPENDIX E: AUTHORIZATION GUIDELINES FOR LABORATORY, OB/GYN, AND RADIOLOGY SERVICES (AUTO PAY LIST) Kaiser Permanente Provider Manual APPENDIX E Revised September 2012 1 KAISER PERMANENTE OF OHIO Appendix E: Authorization Guidelines for Laboratory, Ob/Gyn, and Radiology Services (Auto Pay List) The Laboratory, Ob/Gyn, and Radiology Services listed below may be performed without a Referral if ordered by a Kaiser Permanente Plan Physician and when performed at a Kaiser Permanente Plan Facility. However, the tests or procedures must be medically appropriate for the Member’s diagnosis and the Member must be eligible for coverage on the date of Service. Reimbursement for these Services will be made in accordance with the terms of the Agreement between Kaiser Permanente and the Plan Provider. Kaiser Permanente Provider Manual APPENDIX E Revised September 2012 2 KAISER PERMANENTE OF OHIO KAISER PERMANENTE AUTO PAY LIST HCPCS EFFECTIVE Code PROCEDURE DESCRIPTION DATE 00104 ANESTHESIA FOR ELECTROCONVULSIVE THERAPY 1/1/2007 SUBCUTANEOUS HORMONE PELLET IMPLANTATION (IMPLANTATION OF ESTRADIOL AND/OR TESTOSTERONE PELLETS BENEATH THE 11980 SKIN) 1/1/2005 SIMPLE REPAIR OF SUPERFICIAL WOUNDS OF SCALP, NECK, AXILLAE, EXTERNAL GENITALIA, TRUNK AND/OR EXTREMITIES (INCLUDING 12001 HANDS AND FEE 1/1/2005 LAYER CLOSURE OF WOUNDS OF SCALP, AXILLAE, TRUNK AND/OR 12031 EXTREMITIES (EXCLUDING HANDS AND FEET); 2.5 CM OR LESS 1/1/2005 LAYER CLOSURE OF WOUNDS OF FACE, EARS, EYELIDS, NOSE, LIPS 12051 AND/OR MUCOUS MEMBRANES; 2.
  • Gynecologic and Obstetric Pathology (1127-1316)

    Gynecologic and Obstetric Pathology (1127-1316)

    VOLUME 31 | SUPPLEMENT 2 | MARCH 2018 MODERN PATHOLOGY 2018 ABSTRACTS GYNECOLOGIC AND OBSTETRIC PATHOLOGY (1127-1316) 107TH ANNUAL MEETING GEARED TO LEARN Vancouver Convention Centre MARCH 17-23, 2018 Vancouver, BC, Canada PLATFORM & 2018 ABSTRACTS POSTER PRESENTATIONS EDUCATION COMMITTEE Jason L. Hornick, Chair Amy Chadburn Rhonda Yantiss, Chair, Abstract Review Board Ashley M. Cimino-Mathews and Assignment Committee James R. Cook Laura W. Lamps, Chair, CME Subcommittee Carol F. Farver Steven D. Billings, Chair, Interactive Microscopy Meera R. Hameed Shree G. Sharma, Chair, Informatics Subcommittee Michelle S. Hirsch Raja R. Seethala, Short Course Coordinator Anna Marie Mulligan Ilan Weinreb, Chair, Subcommittee for Rish Pai Unique Live Course Offerings Vinita Parkash David B. Kaminsky, Executive Vice President Anil Parwani (Ex-Officio) Deepa Patil Aleodor (Doru) Andea Lakshmi Priya Kunju Zubair Baloch John D. Reith Olca Basturk Raja R. Seethala Gregory R. Bean, Pathologist-in-Training Kwun Wah Wen, Pathologist-in-Training Daniel J. Brat ABSTRACT REVIEW BOARD Narasimhan Agaram Mamta Gupta David Meredith Souzan Sanati Christina Arnold Omar Habeeb Dylan Miller Sandro Santagata Dan Berney Marc Halushka Roberto Miranda Anjali Saqi Ritu Bhalla Krisztina Hanley Elizabeth Morgan Frank Schneider Parul Bhargava Douglas Hartman Juan-Miguel Mosquera Michael Seidman Justin Bishop Yael Heher Atis Muehlenbachs Shree Sharma Jennifer Black Walter Henricks Raouf Nakhleh Jeanne Shen Thomas Brenn John Higgins Ericka Olgaard Steven Shen Fadi Brimo Jason
  • Department of Obstetrics, Gynecology, and Reproductive Sciences

    Department of Obstetrics, Gynecology, and Reproductive Sciences

    University of Pittsburgh School of Medicine DEPARTMENT OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE SCIENCES ANNUAL REPORT – ACADEMIC YEAR 2019 Tatomir, Shannon DEPARTMENT OF OBSTETRICS, GYNECOLOGY, AND REPRODUCTIVE SCIENCES UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE ANNUAL REPORT Academic Year 2019 July 1, 2018 – June 30, 2019 300 Halket Street Pittsburgh, PA 15213 412.641.4212 1 TABLE OF CONTENTS YEAR IN REVIEW MISSION STATEMENT ..................................................................................................................... 3 CHAIR’S ADDRESS ........................................................................................................................... 4 RECRUITMENTS ............................................................................................................................... 6 DEPARTURES ................................................................................................................................... 7 DEPARTMENT PROFESSIONAL MEMBERS ………………………………………………………………………………...8 DIVISION SUMMARIES OF RESEARCH, TEACHING AND CLINICAL PROGRAMS DIVISION OF GYNECOLOGIC SPECIALTIES .................................................................................... 11 DIVISION OF GYNECOLOGIC ONCOLOGY ..................................................................................... 24 DIVISION OF MATERNAL FETAL MEDICINE .................................................................................. 34 DIVISION OF REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY ...........................................
  • Biomarkers for Early Detection of Cancer: a Systematic Review Towards the Identification of True Cancer Biomarkers for Early Detection

    Biomarkers for Early Detection of Cancer: a Systematic Review Towards the Identification of True Cancer Biomarkers for Early Detection

    Biomarkers for Early Detection of Cancer: A Systematic Review Towards the identification of true cancer biomarkers for early detection Louis-Philippe Fermon Student number: 01304166 Promotor: Prof. Inge Huybrechts Copromotor: Prof. Dr. Veronique Cocquyt A dissertation submitted to Ghent University in partial fulfilment of the requirements for the degree of Master of Medicine in Medicine. Academic year: 2017 – 2018 2 | P a g e Deze pagina is niet beschikbaar omdat ze persoonsgegevens bevat. Universiteitsbibliotheek Gent, 2021. This page is not available because it contains personal information. Ghent Universit , Librar , 2021. 4 | P a g e VOORWOORD “Sic parvis magna” “Greatness from small beginnings” After two years of intensive labour, I’m happy to finally present this dissertation. I would not have been able to do this without the help of my family, friends and of course, my promotor Prof. Dr. Inge Huybrechts. She was always eager to lend support, especially during though moments, and was available when I had any questions or needed any help. Furthermore, I would like to thank a few special people that aided me throughout this process. Firstly, my parents, without whom I would not have been able to bring it home. Secondly, I would like to thank my girlfriend Kimberley and all- time best friend Thomas, who’s advice and support were deeply appreciated. Lastly, I won’t forget all others who were there when I needed them the most. Thank you. 5 | P a g e 6 | P a g e Contents Abstract ........................................................................................................................................ 1 Abstract ........................................................................................................................................ 3 1. Introduction ............................................................................................................................... 4 1.1 Cancer as major health issue..............................................................................................
  • 1 Tumor Markers Currently Utilized in Cancer Care Gaetano

    1 Tumor Markers Currently Utilized in Cancer Care Gaetano

    Tumor markers currently utilized in cancer care Gaetano Romano (gromano at temple dot edu) Department of Biology, College of Science and Technology, Temple University, Bio-Life Science Bldg. Suite 456, 1900 N 12th Street, Philadelphia, PA 19122, U.S.A. DOI http://dx.doi.org/10.13070/mm.en.5.1456 Date last modified : 2015-10-02; original version : 2015-09-25 Cite as MATER METHODS 2015;5:1456 Abstract A review of tumor markers that are currently used in cancer care. Introduction Tumor markers are products that may derive from malignant cells and/or other cells of the organism in response to the onset of cancer [1-5]. Their production may also be induced by noncancerous benign tumors [1-5]. Some tumor markers can be detected in malignant tissues obtained from biopsies [6-19], whereas others can be analyzed in the blood, bone marrow, urine, or other body fluids [20-25]. Sometimes, tumor markers may also be observed in cancer-free subjects, but in much lower doses than oncological patients. In addition, relatively high levels of a certain tumor marker might develop from various non-malignant pathological conditions, such as liver diseases, inflammations, kidney-related dysfunctions, infections and hematological disorders. On these grounds, high levels of a certain tumor marker in the blood, or in other body fluids might indicate the presence of a malignancy. However, per se, this finding is not sufficient to substantiate the diagnosis of a cancer. For this reason, the analysis of tumor markers in the blood, or other fluids must be combined with the analysis of biopsies, or other tests in order to confirm the diagnosis.
  • Review of Non-Invasive Urinary Biomarkers in Bladder Cancer

    Review of Non-Invasive Urinary Biomarkers in Bladder Cancer

    6564 Review Articles on Urothelial Carcinoma Review of non-invasive urinary biomarkers in bladder cancer Hyung-Ho Lee, Sung Han Kim Department of Urology, Urological Cancer Center, Research Institute and Hospital of National Cancer Center, Goyang, Korea Contributions: (I) Conception and design: SH Kim; (II) Administrative support: SH Kim; (III) Provision of study materials or patients: SH Kim; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Sung Han Kim. Department of Urology, Urological Cancer Center, Research Institute and Hospital of National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si Gyeonggi-do 10408, Korea. Email: [email protected]. Abstract: Bladder cancer (BC) is the sixth-most prevalent cancer. The standard diagnostic tool of BC is cystoscopy, whereas cystoscopy has several disadvantages in terms of symptomatic invasiveness and operator- dependency. The urinary markers are attractive because the testing is non-invasive and cost-efficient, and sample collection is easy. Urinary marker is thereby a good tool to detect exfoliated tumor cell in the urine samples for the diagnosis and therapeutic surveillance of BC to supplement the limitations of the cystoscopy. However, they are not recommended as a population-based screening tool because of the low rate of BC prevalence. Although both cystoscopy and urine cytology improve BC diagnostic power, the field still needs additional non-invasive, cost-effective, and highly sensitive and specific diagnostic tools. Various urinary markers with different mechanisms and different targets have been developed and under investigation in these days.